Early research (Phase 1)Ended earlyNCT01611675What this trial is testingLeflunomide+Vemurafenib in V600 Mutant Met. MelanomaWho this might be right forMelanoma Massachusetts General Hospital 3
Not applicableStudy completedNCT03139513What this trial is testingAdult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])Who this might be right forMelanoma Hoffmann-La Roche 200
Testing effectiveness (Phase 2)UnknownNCT05102292What this trial is testingThe Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationWho this might be right forAnaplastic Thyroid CancerATC Shanghai Henlius Biotech 25
Not applicableStudy completedNCT04911998What this trial is testingA Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma PatientsWho this might be right forMelanoma (Skin)Metastatic MelanomaBRAF V600 Mutation Pierre Fabre Medicament 400
Not applicableNo Longer AvailableNCT04507919What this trial is testingManaged Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerWho this might be right forSmall Cell Lung Carcinoma Novartis Pharmaceuticals
Not applicableLooking for participantsNCT07022457What this trial is testingUK ENcorafenib and BInimetinib Real-world Study in MelanomaWho this might be right forMetastatic Melanoma, BRAF V600 Mutation Positive Pierre Fabre Ltd 50
Early research (Phase 1)Study completedNCT02608034What this trial is testingInvestigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateWho this might be right forMetastatic Melanoma, BRAF V600 Mutation Positive Genentech, Inc. 32
Not applicableStudy completedNCT02663232What this trial is testingStudy to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic MelanomaWho this might be right forMetastatic Cancers Hoffmann-La Roche 264
Testing effectiveness (Phase 2)Active Not RecruitingNCT04074096What this trial is testingBinimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisWho this might be right forMalignant MelanomaBRAF V600 MutationBrain Metastases UNICANCER 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05275374What this trial is testingXP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationWho this might be right forCancerBRAF V600 MutationMelanoma+3 more Xynomic Pharmaceuticals, Inc. 221
Testing effectiveness (Phase 2)Study completedNCT01543698What this trial is testingA Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid TumorsWho this might be right forSolid Tumors Harboring a BRAF V600 Mutation Pfizer 189
Not applicableStudy completedNCT01804140What this trial is testingA Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)Who this might be right forMultiple Myeloma, Neoplasms Genentech, Inc. 662
Early research (Phase 1)Study completedNCT01436656What this trial is testingA Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaWho this might be right forMelanoma and Metastatic Colorectal Cancer Pfizer 107
Early research (Phase 1)Ended earlyNCT04294160What this trial is testingSelect Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerWho this might be right forBRAF V600 Colorectal Cancer Novartis Pharmaceuticals 122
Not applicableStudy completedNCT01744860What this trial is testingComparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor SamplesWho this might be right forMalignant Melanoma Hoffmann-La Roche 420
Early research (Phase 1)Study completedNCT01582997What this trial is testingA Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid TumorsWho this might be right forCancer GlaxoSmithKline 12
Not applicableStudy completedNCT06557291What this trial is testingRelapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV MelanomaWho this might be right forBRAF V600 Mutated-Stage III/IV Melanoma Novartis 38
Testing effectiveness (Phase 2)UnknownNCT03514901What this trial is testingTo Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.Who this might be right forMelanoma MetastaticBRAF V600 Mutation Intergruppo Melanoma Italiano 120
Testing effectiveness (Phase 2)UnknownNCT05528406What this trial is testingA Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 MutationWho this might be right forSolid Tumor Shanghai Henlius Biotech 30
Testing effectiveness (Phase 2)Study completedNCT02296112What this trial is testingTrametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 MutationsWho this might be right forRecurrent MelanomaStage IIIB MelanomaStage IIIC Melanoma+1 more Vanderbilt-Ingram Cancer Center 9